Clinical Outcomes after Early and Delayed Radioiodine Remnant Ablation in Patients with Low-Risk Papillary Thyroid Carcinoma: Propensity Score Matching Analysis
- Authors
- Ahn, J[Ahn, Jonghwa]; Jin, M[Jin, Meihua]; Song, E[Song, Eyun]; Jeon, MJ[Jeon, Min Ji]; Kim, TY[Kim, Tae Yong]; Ryu, JS[Ryu, Jin-Sook]; Kim, WB[Kim, Won Bae]; Shong, YK[Shong, Young Kee]; Han, JM[Han, Ji Min]; Kim, WG[Kim, Won Gu]
- Issue Date
- Dec-2020
- Publisher
- KOREAN ENDOCRINE SOC
- Keywords
- Thyroid neoplasms; Thyroid cancer, papillary; Iodine radioisotopes; Recurrence; Prognosis
- Citation
- ENDOCRINOLOGY AND METABOLISM, v.35, no.4, pp.830 - 837
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- ENDOCRINOLOGY AND METABOLISM
- Volume
- 35
- Number
- 4
- Start Page
- 830
- End Page
- 837
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/89706
- DOI
- 10.3803/EnM.2020.747
- ISSN
- 2093-596X
- Abstract
- Background: The clinical outcomes of delayed radioiodine remnant ablation (RRA) therapy in patients with low-risk papillary thyroid carcinoma (PTC) are unclear. We aimed to evaluate the clinical impact of the interval between total thyroidectomy (TT) and RRA therapy in patients with low-risk PTC. Methods: We included 526 patients who underwent TT and RRA for low-risk PTC with a primary tumor size of > 1 cm between 2000 and 2012. Patients were divided into the early (<90 days) and the delayed (>= 90 days) RRA groups based on the interval between TT and RRA. The results of diagnostic whole-body scan (DxWBS), ongoing risk stratification (ORS; response to therapy), and disease-free survival (DFS) were evaluated before and after propensity score matching (PSM). Results: Among the 526 patients, 75 (14.3%) patients underwent delayed RRA; they had more cervical lymph node metastasis and received a higher RRA dose than those who underwent early RRA. The median follow-up period was 9.1 years after initial therapy, and the structural recurrence rate was 1.9%. In DxWBS, 60 patients had focal iodine uptake limited in operative bed, with no significant difference between groups. According to ORS, 78%, 20%, 1%, and 1% patients were classified into excellent, indeterminate, biochemical incomplete, and structural incomplete response groups, respectively. There was no significant difference in ORS or DFS between groups before and after PSM. Conclusion: The timing of the first RRA had no clinical impact in patients with low-risk PTC. Thus, the clinical decision for RRA can be determined > 3 months after TT considering other prognostic factors.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/89706)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.